|
|
|
|
|
|
|
08.12.25 - 14:03
|
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
|
|
|
-Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations
-Anticipated to be highly synergistic with Mirum's liver expertise and proven global commercial capabilities
-HDV: Large, high unmet-need rare liver disease with no FDA-approved therapies
-Top-line Phase 3 results expected in 2H 2026
-Conference call today, December 8, 2025 at 8:30 am ET/5:30 am PT
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced its entry into a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. The transaction would add worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV) to Mirum's portfolio of rare liver programs. This acquisition is expected to advance Mirum's leadership in rare disease, bu...
|
|
|
|
|
|
|
|
|
|
|
|
|
11.11.25 - 02:03
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on November 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 53,500 shares of common stock and 27,950 restricted stock units (“RSUs”) to 11 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $69.71 per share, Mirum's closing trading price on November 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum thr...
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 22:03
|
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
|
|
|
- Third quarter 2025 total revenue of $133 million
- 2025 revenue guidance updated to $500 to $510 million
- Phase 2b VISTAS topline data expected second quarter of 2026
- Conference call to provide business updates today, November 4 at 1:30 p.m. PT / 4:30 p.m. ET
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update.
“Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore the strength of our commercial medicines with continued strong performance. We also made important progress across the pipeline, including completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating our Phase 2 study in Fragile X Syndrome.”
Commercial: Full year revenue guidance $500 to $510 million
Third quarter...
|
|
|
28.10.25 - 21:03
|
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report third quarter 2025 financial results on November 4, 2025. Mirum will also host a conference call to discuss the third quarter 2025 financial results and recent corporate progress.
Conference call details:
Tuesday November 4th, 2025
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:
US/Toll-Free: +1 833 470 1428
International: +1 646 844 6383
Access Code: 299722
You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor...
|
|
|
|
|
11.10.25 - 01:51
|
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on October 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 45,800 shares of common stock and 22,850 restricted stock units (“RSUs”) to eight new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $72.71 per share, Mirum's closing trading price on October 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum th...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
